Adlai Nortye (ANL) Assets Average (2023 - 2026)
Adlai Nortye (ANL) posted quarterly Assets Average of $53.2 million for Q4 2025, down 40.5% year-over-year from $89.5 million in Q4 2024, and down 25.7% quarter-over-quarter from $71.7 million in Q2 2025.
Analysis
Adlai Nortye (ANL) Assets Average (2023 - 2026) Analysis & Trends
Adlai Nortye (ANL) has reported Assets Average for 3 consecutive years, with $53.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Assets Average fell 40.5% year-over-year to $53.2 million; the TTM figure through Dec 2025 stood at $53.2 million (down 40.5% YoY), while the FY2025 annual figure was $52.9 million, down 47.53% from the prior year.
- Assets Average retreated to $53.2 million in Q4 2025 per ANL's latest filing, from $71.7 million in the prior quarter.
- Across five years, Assets Average topped out at $118.9 million in Q2 2024 and bottomed at $53.2 million in Q4 2025.
- Historically, Assets Average has averaged $86.9 million across 3 years, with a median of $89.5 million in 2024.
- Annual changes were most pronounced in 2024 — Assets Average fell 11.75% — and 2025, when it tumbled 40.5%.
- Adlai Nortye's Assets Average stood at $101.4 million in 2023, then declined by 11.75% to $89.5 million in 2024, then sank by 40.5% to $53.2 million in 2025.
- Business Quant data shows ANL's Assets Average at $53.2 million in Q4 2025, $71.7 million in Q2 2025, and $89.5 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.22 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 3.29 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.86 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Adlai Nortye | 500.08 Mn | 268.19 Mn | - | 141.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 141.40 Mn |
| Dec 31, 2025 | 53.24 Mn |
| Jun 30, 2025 | 71.66 Mn |
| Dec 31, 2024 | 89.48 Mn |
| Jun 30, 2024 | 118.94 Mn |
| Dec 31, 2023 | 101.39 Mn |